Stelexis Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Stelexis Therapeutics's estimated annual revenue is currently $1.4M per year.(i)
  • Stelexis Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Stelexis Therapeutics has 9 Employees.(i)
  • Stelexis Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Stelexis Therapeutics?

Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. Stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. Deerfield founded Stelexis Therapeutics in 2017 together with scientific founders, Drs. Ulrich Steidl, Evripidis Gavathiotis, Amit Verma and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Medicine, New York and Dr. Derrick Rossi of Boston Children’s Hospital, Harvard Medical School.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$1.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.2M90%$14.4M
#2
$0.7M9-10%N/A
#3
$0.1M9-18%$200.9M
#4
$0.2M9-18%$67M
#5
$0.1M9-25%N/A